Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Feb;25(2):179–185. doi: 10.1111/j.1365-2125.1988.tb03289.x

The influence of beta-adrenoceptor blockers with and without intrinsic sympathomimetic activity on heart rate, arrhythmias and ST-T segments, using ambulatory electrocardiography.

R J Northcote 1, D Ballantyne 1
PMCID: PMC1386472  PMID: 3358881

Abstract

1. Ambulatory electrocardiography was used to compare the effects of propranolol and pindolol on symptoms, heart rate, arrhythmias and ST segments. Seventeen males (mean age 54 years) with a diagnosis of chronic stable angina pectoris (New York Heart Association Class II-III) were studied. Patients were treated on a double-blind cross-over basis with propranolol 80 mg three times daily or pindolol 5 mg three times daily for 14 days each. During the last 48 h of each treatment period ambulatory electrocardiography was performed. 2. Propranolol resulted in a significantly lower mean hourly, mean 24 h and minimum heart rate. Likewise propranolol caused a lower mean daytime and nocturnal heart rate. There was no significant difference in the frequency of angina between the treatments. The number of episodes of ST segment depression was not significantly different between the two drugs, although there was a trend in favour of propranolol. 3. Both the mean 24 h ST level and the maximum ST segment depression were lower during treatment with pindolol. Propranolol was associated with a total of 117 nocturnal pauses or episodes of asystole ranging in length from 1.5 to 2.8 s. During treatment with pindolol only one such period occurred. The number of premature ventricular contractions occurring during treatment with pindolol (1316 beats) was less than on propranolol (2010) and the mean hourly frequency of premature ventricular contractions was significantly lower during pindolol administration. 4. Pindolol is not significantly different from propranolol in the control of symptomatic and asymptomatic myocardial ischaemia and is associated with fewer premature ventricular contractions. However, there is no advantage in using pindolol in chronic stable angina.

Full text

PDF
179

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arstila M., Kallio V., Wendelin H. Propranolol and LB 46 (prinodolol) in angina pectoris. A comparative long-term ergometric study. Ann Clin Res. 1973 Apr;5(2):91–100. [PubMed] [Google Scholar]
  2. Bruce R. A., Gey G. O., Jr, Cooper M. N., Fisher L. D., Peterson D. R. Seattle Heart Watch: initial clinical, circulatory and electrocardiographic responses to maximal exercise. Am J Cardiol. 1974 Apr;33(4):459–469. doi: 10.1016/0002-9149(74)90602-x. [DOI] [PubMed] [Google Scholar]
  3. Chierchia S., Gallino A., Smith G., Deanfield J., Morgan M., Croom M., Maseri A. Role of heart rate in pathophysiology of chronic stable angina. Lancet. 1984 Dec 15;2(8416):1353–1357. doi: 10.1016/s0140-6736(84)92055-5. [DOI] [PubMed] [Google Scholar]
  4. Dwyer E. M., Jr, Pepe A. J., Pinkernell B. H. Effects of beta-adrenergic blockade with pindolol versus placebo in coronary patients with stable angina pectoris. Am Heart J. 1982 May;103(5):830–833. doi: 10.1016/0002-8703(82)90395-7. [DOI] [PubMed] [Google Scholar]
  5. Frishman W., Kostis J., Strom J., Hossler M., Elkayam U., Goldner S., Silverman R., Davis R., Weinstein J., Sonnenblick E. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6. A comparison of pindolol and propranolol in treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J. 1979 Oct;98(4):526–535. doi: 10.1016/0002-8703(79)90261-8. [DOI] [PubMed] [Google Scholar]
  6. Gianelly R. E., Goldman R. H., Treister B., Harrison D. C. Propranolol in patients with angina pectoris. Ann Intern Med. 1967 Dec;67(6):1216–1225. doi: 10.7326/0003-4819-67-6-1216. [DOI] [PubMed] [Google Scholar]
  7. Grant R. H., Keelan P., Kernohan R. J., Leonard J. C., Nancekievill L., Sinclair K. Multicenter trial of propranolol in angina pectoris. Am J Cardiol. 1966 Sep;18(3):361–365. doi: 10.1016/0002-9149(66)90054-3. [DOI] [PubMed] [Google Scholar]
  8. Harston W. E., Friesinger G. C. Randomized double-blind study of pindolol in patients with stable angina pectoris. Am Heart J. 1982 Aug;104(2 Pt 2):504–511. doi: 10.1016/0002-8703(82)90147-8. [DOI] [PubMed] [Google Scholar]
  9. Hinkle L. E., Jr, Carver S. T., Stevens M. The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol. 1969 Nov;24(5):629–650. doi: 10.1016/0002-9149(69)90451-2. [DOI] [PubMed] [Google Scholar]
  10. Kostis J. B., Frishman W., Hosler M. H., Thorsen N. L., Gonasun L., Weinstein J. Treatment of angina pectoris with pindolol: the significance of intrinsic sympathomimetic activity of beta blockers. Am Heart J. 1982 Aug;104(2 Pt 2):496–504. doi: 10.1016/0002-8703(82)90146-6. [DOI] [PubMed] [Google Scholar]
  11. Morganroth J., Michelson E. L., Horowitz L. N., Josephson M. E., Pearlman A. S., Dunkman W. B. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation. 1978 Sep;58(3 Pt 1):408–414. doi: 10.1161/01.cir.58.3.408. [DOI] [PubMed] [Google Scholar]
  12. Quyyumi A. A., Wright C. A., Mockus L. J., Fox K. M. Mechanisms of nocturnal angina pectoris: importance of increased myocardial oxygen demand in patients with severe coronary artery disease. Lancet. 1984 Jun 2;1(8388):1207–1209. doi: 10.1016/s0140-6736(84)91693-3. [DOI] [PubMed] [Google Scholar]
  13. Quyyumi A. A., Wright C., Mockus L., Fox K. M. Effect of partial agonist activity in beta blockers in severe angina pectoris: a double blind comparison of pindolol and atenolol. Br Med J (Clin Res Ed) 1984 Oct 13;289(6450):951–953. doi: 10.1136/bmj.289.6450.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reale A., Motolese M. Partial agonist activity of beta-adrenergic blocking agents and cardiac performance: a review. Eur Heart J. 1981 Jun;2(3):245–251. doi: 10.1093/oxfordjournals.eurheartj.a061202. [DOI] [PubMed] [Google Scholar]
  15. Sainani G. S., Mukherjee A. K. A double blind drug trial of LB-46 (visken) in angina pectoris. Indian Heart J. 1972 Jun;24(Suppl):192–196. [PubMed] [Google Scholar]
  16. Sowton E., Hamer J. Hemodynamic changes after beta adrenergic blockade. Am J Cardiol. 1966 Sep;18(3):317–320. doi: 10.1016/0002-9149(66)90048-8. [DOI] [PubMed] [Google Scholar]
  17. Thadani U., Davidson C., Singleton W., Taylor S. H. Comparison of five beta-adrenoreceptor antagonists with different ancillary properties during sustained twice daily therapy in angina pectoris. Am J Med. 1980 Feb;68(2):243–250. doi: 10.1016/0002-9343(80)90361-7. [DOI] [PubMed] [Google Scholar]
  18. Thadani U., Sharma B., Meeran M. K., Majid P. A., Whitaker W., Taylor S. H. Comparison of adrenergic beta-receptor antagonists in angina pectoris. Br Med J. 1973 Jan 20;1(5846):138–142. doi: 10.1136/bmj.1.5846.138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wolfson S., Gorlin R. Cardiovascular pharmacology of propranolol in man. Circulation. 1969 Oct;40(4):501–511. doi: 10.1161/01.cir.40.4.501. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES